---
title: "Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference | VCRE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296995310.md"
description: "Vicore Pharma Holding AB announced it will present at the Pareto Securities 17th Annual Healthcare Conference in Stockholm on September 2, 2026. CFO Hans Jeppsson will lead the presentation and participate in one-on-one meetings. Vicore is a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists for respiratory diseases."
datetime: "2026-08-25T22:20:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296995310.md)
  - [en](https://longbridge.com/en/news/296995310.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296995310.md)
generator: "portal-rs"
---

# Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference | VCRE Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.

Location: Hotel At Six, Stockholm, Sweden  
Format: Presentation and 1×1 meetings  
Presentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CEST  
Participant: Hans Jeppsson, Chief Financial Officer

**For more information, please contact:**  
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

**About Vicore Pharma**  
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

**Attachments**  
Vicore Pharma to Present at the Pareto Securities 17th Annual Healthcare Conference

**SOURCE:** Vicore Pharma Holding

View the original press release on ACCESS Newswire

### Related Stocks

- [VCRE.US](https://longbridge.com/en/quote/VCRE.US.md)

## Related News & Research

- [Vicore Pharma to Participate in Upcoming Healthcare Conferences | VCRE Stock News](https://longbridge.com/en/news/297605596.md)
- [Vicore Pharma Holding AB (publ) GAAP EPS of SEK -0.51, revenue of SEK 2.2M](https://longbridge.com/en/news/296653880.md)
- [Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN](https://longbridge.com/en/news/297882653.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [Vidac Pharma board member Dr. Max Herzberg sells shares for EUR 5,375](https://longbridge.com/en/news/297966632.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**